Search results
Results from the WOW.Com Content Network
As an example, the incidence of congestive heart failure is 4.7%, 26% and 48% respectively when patients received doxorubicin at 400 mg/m 2, 550 mg/m 2 and 700 mg/m 2. [4] Therefore, the lifetime cumulative doxorubicin exposure is limited to 400–450 mg/m 2 in order to reduce congestive heart failure incidence to less than 5%, although ...
Example of uses, and other notes 7+3, also known as DA or DAC in case of daunorubicin, or IA or IAC in case of idarubicin use 7 days of Ara-C plus 3 days of an anthracycline antibiotic, either daunorubicin (DA or DAC variant) or idarubicin (IA or IAC variant) Acute myelogenous leukemia, excluding acute promyelocytic leukemia: ABVD
Use in pregnancy may harm the fetus. [2] Daunorubicin is in the anthracycline family of medication. [3] It works in part by blocking the function of topoisomerase II. [2] Daunorubicin was approved for medical use in the United States in 1979. [2] It is on the World Health Organization's List of Essential Medicines. [4]
Doxorubicin, sold under the brand name Adriamycin among others, is a chemotherapy medication used to treat cancer. [10] This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. [10] It is often used together with other chemotherapy agents. [10] Doxorubicin is given by injection into a vein. [10]
ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs: It consists of concurrent treatment with the chemotherapy drugs:
Currently, there are four main anthracyclines in medical use: Doxorubicin; Daunorubicin (doxorubicin precursor) Epirubicin (a doxorubicin stereoisomer) Idarubicin (a daunorubicin derivative) [17] Idarubicin is able to pass through cell membranes easier than daunorubicin and doxorubicin because it possesses less polar subunits, making it more ...
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...
R-miniCHOP is indicated in elderly patients (>80 years) with diffuse large B-cell lymphoma due to less toxicity from the reduced dose in comparison to R-CHOP.. R-Maxi-CHOP is used in mantle cell lymphoma and is given in 21-day intervals, alternating with R-HDAC (rituximab + high-dose cytarabine).